MX2015006710A - Tratamiento de las enfermedades pulmonares. - Google Patents

Tratamiento de las enfermedades pulmonares.

Info

Publication number
MX2015006710A
MX2015006710A MX2015006710A MX2015006710A MX2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A MX 2015006710 A MX2015006710 A MX 2015006710A
Authority
MX
Mexico
Prior art keywords
pulmonary disease
treatment
reducing
lung
alleviating
Prior art date
Application number
MX2015006710A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2015006710A publication Critical patent/MX2015006710A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con métodos para tratar, reducir el riesgo, prevenir o aliviar los síntomas de una enfermedad o trastorno pulmonar mediante la reducción o supresión de la inflamación pulmonar y la promoción de la reparación pulmonar, usando un compuesto de la fórmula A o una sal farmacéuticamente aceptable de este.
MX2015006710A 2012-11-28 2013-11-26 Tratamiento de las enfermedades pulmonares. MX2015006710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
MX2015006710A true MX2015006710A (es) 2016-01-15

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006710A MX2015006710A (es) 2012-11-28 2013-11-26 Tratamiento de las enfermedades pulmonares.

Country Status (19)

Country Link
US (3) US20140148428A1 (es)
EP (1) EP2925328A1 (es)
JP (1) JP6270171B2 (es)
KR (1) KR102106186B1 (es)
CN (1) CN104853758A (es)
AU (1) AU2013352288B2 (es)
BR (1) BR112015012312A2 (es)
CA (1) CA2891348C (es)
CL (1) CL2015001442A1 (es)
HK (1) HK1211844A1 (es)
IL (1) IL239025B (es)
MX (1) MX2015006710A (es)
MY (1) MY170802A (es)
NZ (1) NZ708501A (es)
PH (1) PH12015501108A1 (es)
RU (1) RU2693382C2 (es)
SG (1) SG11201503697TA (es)
TW (1) TWI636786B (es)
WO (1) WO2014085474A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3594348T1 (sl) 2013-11-22 2022-04-29 Mina Therapeutics Limited Sestavki kratko aktivirajoče rna c/ebp alfa in postopki uporabe
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
WO2016079517A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EA033603B1 (ru) * 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA033445B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
WO2016079519A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
US11072631B2 (en) * 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
MA45761A (fr) * 2015-10-07 2021-04-21 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
US11168107B2 (en) 2016-02-10 2021-11-09 Dr. Reddy's Laboratories Limited Amine salt of obeticholic acid
CN109152787A (zh) * 2016-03-31 2019-01-04 英特塞普特医药品公司 具有优越的溶出性的口服制剂
JP6968821B2 (ja) * 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN109415405A (zh) * 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
JP2019529481A (ja) * 2016-09-30 2019-10-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の結晶形態
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
WO2019085963A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU570013B2 (en) 1982-10-08 1988-03-03 Glaxo Group Limited Medicament inhaler
CA1272917A (en) 1985-07-30 1990-08-21 Paul Kenneth Rand Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
AU698364B2 (en) 1995-03-10 1998-10-29 Minnesota Mining And Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2440680C (en) * 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
EP1696910A4 (en) * 2003-09-26 2009-12-09 Smithkline Beecham Corp COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
SI2712617T1 (sl) 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2008000643A1 (en) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
BRPI0916735B8 (pt) * 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
CA2744135C (en) * 2008-11-19 2017-07-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
SG178562A1 (en) * 2009-08-25 2012-03-29 Victor Ling Polyhydroxylated bile acids for treatment of biliary disorders
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
SI3336097T1 (sl) * 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline

Also Published As

Publication number Publication date
KR20150089052A (ko) 2015-08-04
JP6270171B2 (ja) 2018-01-31
PH12015501108B1 (en) 2015-08-17
CA2891348C (en) 2020-04-28
TWI636786B (zh) 2018-10-01
US20160213689A1 (en) 2016-07-28
US20180064729A1 (en) 2018-03-08
JP2016500111A (ja) 2016-01-07
IL239025A0 (en) 2015-07-30
CN104853758A (zh) 2015-08-19
MY170802A (en) 2019-08-28
BR112015012312A2 (pt) 2017-07-11
US20140148428A1 (en) 2014-05-29
RU2015122027A (ru) 2017-01-10
SG11201503697TA (en) 2015-06-29
CL2015001442A1 (es) 2015-08-28
EP2925328A1 (en) 2015-10-07
KR102106186B1 (ko) 2020-05-04
NZ708501A (en) 2019-03-29
HK1211844A1 (en) 2016-06-03
WO2014085474A1 (en) 2014-06-05
CA2891348A1 (en) 2014-06-05
IL239025B (en) 2021-04-29
AU2013352288B2 (en) 2017-11-23
PH12015501108A1 (en) 2015-08-17
AU2013352288A1 (en) 2015-06-04
TW201434469A (zh) 2014-09-16
RU2693382C2 (ru) 2019-07-02

Similar Documents

Publication Publication Date Title
PH12015501108A1 (en) Treatment of pulmonary disease
IN2015DN02573A (es)
IN2015DN01156A (es)
IN2014DN09434A (es)
MY178621A (en) Deuterated cftr potentiators
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
IN2014DN09173A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2012062925A3 (en) Compounds and methods for treating pain
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
MX2015007916A (es) Peri-carbinoles.
JO3510B1 (ar) استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015008187A (es) Inhibidores de alk deuterados.
ZA201308391B (en) Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis

Legal Events

Date Code Title Description
FG Grant or registration